GRK4 Knockout 293T Cell Line

Description

GRK4 Knockout 293T Cell Line is engineered from human embryonic kidney 293T cells using CRISPR/Cas9 technology to disrupt the G Protein-Coupled Receptor Kinase 4 (GRK4) gene, a critical regulator of dopaminergic and adrenergic receptor signaling that modulates blood pressure homeostasis and renal function. This knockout model exhibits impaired receptor desensitization while maintaining 293T cells’ characteristic adherent growth with epithelial morphology and high transfection efficiency. The cell line provides an essential tool for studying hypertension pathogenesis, dopamine receptor dysregulation, and G protein-coupled receptor (GPCR) trafficking, particularly in research involving salt-sensitive hypertension and renal dopamine signaling. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through genomic PCR, Sanger sequencing, and functional assays demonstrating altered β-arrestin recruitment. The cell line has undergone rigorous quality control and is certified free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.